

Recent patent applications in drug screening

Patent #	Subject	Assignee(s)	Inventor(s)	Priority application date	Publication date
WO 2006132116, EP 1767929	A cell electrophysiology measurement device for drug screening, comprising a thin sheet of material layers of different thickness. A frame made of a material layer is made to contact the outer periphery of the thin sheet.	Matsushita Electric Industrial Co. (Osaka, Japan)	Kojima M, Nakatani M, Yoshida T	6/7/2005	12/14/2006, 3/28/2007
WO 2007025987	A self-replicating DNA plasmid comprising a DNA tag having a nucleotide sequence to encode a specific peptide tag; useful for the production of therapeutic proteins, polypeptides and peptides for drug screening.	Novo Nordisk (Bagsvaerd, Denmark)	Schiodt CB, Woeldike H	8/30/2005	3/8/2007
WO 2007004587	A malignant tumor cell suppressor protein having an amino acid sequence of SEQ ID No. 1, or an amino acid sequence having deletion, substitution or addition of one or more amino acids in SEQ ID No. 1.	RIKEN (Saitama, Japan), Tama TLO (Tokyo)	Andoh T, Hayashizaki Y, Okazaki Y, Sugahara T	6/30/2005	1/11/2007
WO 2007003675	A nonhuman transgenic animal that expresses, exclusively in astrocytes, an active variant of calcineurin; useful for the study, treatment and monitoring of inflammatory neurodegenerative disease, also in drug screening.	Consejo Superior de Investigaciones Cientificas (Serrano, Spain)	Fernandez Garcia AM, Fernandez Hernandez S, Torres Aleman I	7/6/2005	1/11/2007
WO 2007002568	A population of undifferentiated human embryonic stem cells, or a population of cells differentiated from it, comprising cells that have been genetically altered so that a promoter that responds to a metabolic or toxicologic change in the cell controls expression of a reporter gene; useful in systems for drug testing and screening.	Clark H, Geron (Menlo Park, CA, USA)	Clark AJ, Wolf CR	6/22/2005	1/4/2007
US 20060292695	Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells. Drug testing comprises combining a drug with human embryonic stem cells that have been genetically altered so that the promoter that responds to metabolic or toxicologic change in cells controls the expression of a reporter gene.	Roslin Institute (Midlothian, UK), CXR Biosciences (Dundee, UK)	Clark AJ, Clark H, Wolf CR	6/22/2005	12/28/2006
US 20060292694	A cell population differentiated from human embryonic stem cells, comprising genetically altered cells so that a promoter that responds to a metabolic or toxicologic change in the cell controls expression of a reporter gene.	Roslin Institute (Midlothian, UK), CXR Biosciences (Dundee, UK)	Clark AJ, Clark H, Wolf CR	6/22/2005	12/28/2006
US 20060275840	A solid support for cell-based assays comprising particles including a matrix and having a scintillant substance that has been coated onto or integrated into the matrix of the particles, and adapted for cell growth.	GE Healthcare (Chalfont St. Giles, UK)	Ismail RA, O'Beirne GB, Thomas N	11/10/2000	12/7/2006
EP 1728858, WO 2006128681	Use of specific cell line for deriving human primitive endodermal stem cells, primitive epithelial liver cells or matured epithelial liver cells from human embryonic stem cells; useful for drug screening.	AbCys (Paris)	Barbet R, Hatzfeld J, Herpe YE, Laabi Y	5/31/2005	12/6/2006, 12/7/2006
US 7141652	An isolated antibody that specifically binds to polypeptide containing 116 amino acid sequences as given in the specification; useful for drug screening.	Genentech (S. San Francisco, CA, USA)	Goddard A, Godowski PJ, Gurney AL, Wood WI	10/7/1998	11/28/2006

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (<http://www.thomson.com/scientific>).